|
|
Treatment-Resistant HCV Patients Respond to Protease Inhibitor-Based Therapy
|
| Link ID |
16279 |
| Title |
Treatment-Resistant HCV Patients Respond to Protease Inhibitor-Based Therapy |
| Url |
http://www.medscape.com/viewarticle/703947?src=rss |
| Description |
The investigational protease inhibitor telaprevir (Tibotec and Vertex Pharmaceuticals), added to standard treatment for hepatitis C virus (HCV) infection, produced a sustained virologic response in more than half of patients with treatment-refractory disease, late-breaking clinical trial results show. Reuters Health Information |
| Category |
Articles > Gastroenterology |
| Keywords |
|
| Date |
Jun 6, 2009 |
| Contact Name |
|
| Email |
|
Write a Review
Add to My Favorite
Refer it to Friend
Report Broken Link
|
|
Other links at Articles > Gastroenterology |
| 3. |
New Colorectal Cancer Susceptibility Loci Identified
|
|
|
Genome-wide association scans have identified new colorectal cancer susceptibility loci on 11q23, 10p14, and 8q23.3, according to the findings of two studies appearing in the March 30th advance online issue of Nature Genetics. Reuters Health Information
|
|
|
